Effectiveness and trend forecasting of tuberculosis diagnosis after the introduction of GeneXpert in a city in south-eastern Brazil

Thaís Zamboni Berra, Dulce Gomes, Antônio Carlos Vieira Ramos, Yan Mathias Alves, Alexandre Tadashi Inomata Bruce, Luiz Henrique Arroyo, Felipe Lima dos Santos, Ludmilla Leideanne Limirio Souza, Juliane de Almeida Crispim, Ricardo Alexandre Arcêncio

1 Department of Maternal-Infant and Public Health Nursing, University of São Paulo at Ribeirão Preto College of Nursing, Ribeirão Preto, São Paulo, Brazil, 2 Mathematics Department in University of Évora, Évora, Portugal

Abstract

Background
To evaluate the effectiveness of a rapid molecular test for the detection of tuberculosis (TB) and to predict the rates of disease in a municipality of Brazil where TB is endemic.

Methods
An ecological study was carried out in Ribeirão Preto-SP on a population of TB cases notified between 2006 and 2017. Monthly TB incidence rates and the average monthly percentage change (AMPC) were calculated. In order to identify changes in the series, the breakpoint technique was performed; the rates were modelled and predictions of the incidence of TB until 2025 were made.

Results
AMPC showed a fall of 0.69% per month in TB and human immunodeficiency virus (TB-HIV) co-infection, a fall of 0.01% per month in general and lung TB and a fall of 0.33% per month in extrapulmonary TB. With the breakpoint technique, general and pulmonary TB changed in structure in late 2007, and extrapulmonary TB and TB-HIV co-infection changed in structure after 2014, which is considered the cut-off point. The IMA(3) models were adjusted for general and pulmonary TB and TB-HIV co-infection, and the AR(5) models for extrapulmonary TB, and predictions were performed.

Conclusions
The rapid molecular test for TB is the method currently recommended by the WHO for the diagnosis of the disease and its main advantage is to provide faster, more accurate results and to already check for drug resistance. It is necessary that professionals encourage the
use of this technology in order to optimize the diagnosis so that the treatment begins as quickly as possible and in an effective way. Only by uniting professionals from all areas with health policies aimed at early case identification and rapid treatment initiation it is possible to break the chain of TB transmission so that its rates decrease and the goals proposed by the WHO are achieved.

Background

Tuberculosis (TB) is a disease that affects millions of people annually. It is classified as one of the most lethal infectious diseases in the world and it is the main cause of death among people diagnosed with HIV (human immunodeficiency virus), with the number of deaths from TB greater than those caused by AIDS (Acquired Immunodeficiency Syndrome) today [1].

In 2019, the World Health Organization (WHO) estimated that there were ten million new cases of TB in the world, with 56% of these cases being in men, 32% in women and 12% in children under 15 years of age; among those, 8.2% were people living with HIV. It is also estimated that there were 1.4 million deaths from TB and 208,000 deaths due to co-infection by TB and human immunodeficiency virus (TB-HIV). In Brazil, approximately 74,000 new cases were diagnosed in 2019, with more than 13,000 cases of relapse of the disease, and about 500 cases of drug addiction [1].

Regarding the diagnostic technologies available in the Brazilian scenario, it is important to highlight that smear microscopy is the routine test in the Brazilian health system (called Sistema Único de Saúde–SUS), and that a culture test is considered as the gold standard for identifying the disease [2]; however, because of the delay in obtaining results due to the prolonged turnaround time of *Mycobacterium tuberculosis* (on average four to eight weeks) and the high complexity, a culture is rarely used for making decisions related to the treatment of a person affected by the disease [3,4]. In addition, it is worth noting that for the diagnosis of TB, imaging examination, clinical evaluation and histology or cytology can also be considered for cases of extrapulmonary TB.

After almost a century of stagnation regarding TB diagnostic techniques, the WHO, in 2010, approved the use of the GeneXpert® MTB/RIF system to perform rapid molecular testing for TB, which is a molecular method based on the real-time PCR (polymerase chain reaction). This is an amplification test for nucleic acids which is used to detect the DNA of *M. tuberculosis* and to screen strains that are resistant to rifampicin, one of the main antibiotics used in the treatment of TB [5].

In a survey of the scientific literature conducted in the main databases, no studies were found that assessed the impact of the rapid molecular test for TB for the detection of cases of disease in the routine activities of health teams. However, studies show that the test performed by the GeneXpert® MTB/RIF system is highly sensitive to pulmonary TB (transmissible form of the disease) [6] and is also the most cost-effective [7–9], as it provides faster results without requiring sample treatment or specialized human resources, thus allowing treatment to begin immediately [10]. However, despite this good cost-benefit, it is worth noting that, in general, it is not a technology considered to be low cost, which can be considered a major disadvantage for developing countries.

For this reason, this study aimed to evaluate the effectiveness of GeneXpert® MTB/RIF for the detection of pulmonary TB, extrapulmonary TB and TB-HIV co-infection and to predict the rates of the disease in the coming years if the routine activities of the health teams in a municipality of south-eastern Brazil are maintained.
Methods

Research design and scenario

This was an ecological study [11] carried out in Ribeirão Preto, a municipality in the interior of São Paulo. With regard to the care of people in the municipality with TB, the Basic Health Units (BHSs) are responsible for carrying out active searches for respiratory symptoms, with the collection of sputum smear microscopy and/or X-ray requests. However, the treatment and follow-up of TB cases is performed in specialized outpatient clinics for infectious patients [12].

It is noteworthy that the rapid molecular test for TB in Ribeirão Preto, which involves using the GeneXpert MTB/RIF system, was implemented and started to be used as a diagnostic technology for TB in November 2014; this was the cut-off point considered in the study.

Population

The study population consisted of TB cases notified to the Tuberculosis Patient Control System (TBWeb) from 2006 to 2017, which were made available through the Epidemiological Surveillance Division of the Ribeirão Preto Municipal Secretariat.

In the state of São Paulo, a decision has been made to use a single system for the notification and monitoring of people with TB. In TBWeb, which started to be used effectively from 2006, notifications are made online; the main advantage of this system is the uniqueness of each patient’s records, and the automatic communication in cases of transfer and hospitalization [13].

Confirmed cases of TB among individuals residing in Ribeirão Preto were considered. Only one record per person was adopted as the selection criterion, with the most current record being selected if there was more than one entry in the system.

The notified TB cases were separated in order to show the differences in the time series for different groups in the municipality: general TB, pulmonary TB, extrapulmonary TB and TB-HIV co-infection.

Analysis plan

Calculation of incidence rates. The monthly incidence rates of TB in the municipality were calculated as the number of cases per month (corrected by the number of days in that month) divided by the corresponding estimated population for the investigation period (2006 to 2017), thus resulting in 144 monthly time observations [14]. Subsequently, the Average Monthly Percentage Change (AMPC) of incidence rates was calculated, identifying, in average percentage terms, any increase or decrease in rates during the study period.

Detection of structural changes. In an analysis of time series, in addition to the usual variability observed over time, the data can also be influenced by various types of event that can cause structural changes. Thus, in order to identify possible changes in the series, the R CRAN package strucchange was used [15].

Basically, a \( y_t \) series is considered and it is assumed that there are \( m \) breakpoints in the series, in which the coefficients change from one stable regression relationship to another. There are, therefore, \( m + 1 \) segments in which the regression coefficients are constant and the model can be rewritten as:

\[
y_t = x_t' \beta_j + u_t \quad (t = t_j + 1, \ldots, t_{j+1}, \ j = 1, \ldots, m + 1)
\]

with \( x_t \) being the vector of the co-variables, \( \beta_j \) (where \( j \) denotes the segment index) the
corresponding regression coefficients, and \( u_t \) white noise (that is, an uncorrelated series, with zero mean and constant variance) [16].

**Modelling and forecasting future values.** To model the TB rates, and to predict their future values, incidence rates smoothed by first-order moving averages were considered, as proposed by Becketti [17], using the model for linear time series called the autoregressive integrated moving average (ARIMA) model. The analysis steps proposed by Box and Jenkins [18] were adapted for the chosen model, based on the data structure itself: Identification, Estimation, Verification and Forecasting.

An ARIMA model \((p, d, q)\) allows the variability of a time-related, linear, stationary \((d = D = 0)\) or non-stationary (otherwise) process to be described.

The letters \( p \) and \( q \) represent, respectively, the number of parameters of the autoregressive parts and the moving averages within the period, and the letter \( d \) represents the degrees of simple differentiation necessary to transform a non-stationary series into a stationary one [19].

An ARIMA model can be written as follows:

\[
\Delta(B') \Phi(B)(1 - B)^d(1 - B')^D T(X_t) = \Psi(B') \Theta(B) Z_t
\]

where:

\[
\Phi(B) = 1 - \phi_1 B - \phi_2 B^2 - \cdots - \phi_p B^p, \Theta(B) = 1 - \theta_1 B - \theta_2 B^2 - \cdots - \theta_q B^q
\]

are, respectively, the autoregressive and the moving average polynomials. \( T \) is the transformation to stabilize the variance, if this is necessary, and \( Z_t \) represents the white noise process (a non-correlated process, with zero mean and constant variance).

The KPSS unit root test was performed to determine whether the series was stationary or not, using a significance level of 5%. For a non-stationary series, it is necessary to resort to the usual transformation techniques (Box–Cox and simple differentiations) in order to transform the series into a stationary one and then to determine, through the empirical autocorrelation and partial autocorrelation functions, the \( p \) and orders of the ARIMA model.

To estimate the model parameters, the maximum likelihood method was used. For the validation of the model, namely in the analysis of residues, the usual tests of absence of autocorrelation (Portmanteau tests: Ljung–Box and Box–Pierce), randomness (Rank and Turning Point tests), normality (Kolmogorov–Smirnov test) and the \( t \) test of average nullity were performed.

It is worth mentioning that the choice of the best model was made taking into account the lowest values of the Akaike information criterion (AIC). Subsequently, data and trend forecasts were made for an eight-year period (2018 to 2025).

A set of tests using the last two years (2016 to 2017) was used to assess the predictive performance of the models. The following measures were considered in order to evaluate this predictive performance: Root Mean Square Error (RMSE), which indicates the difference between the values predicted by a model and the observed values, Mean Absolute Error (MAE), which is a measure of the accuracy of a forecast in the estimation of trends, and Mean Absolute Percentage Error (MAPE), which is the percentage of the predicted values that are incorrect. Forecasts were then made based on the adjusted models for the eight-year period (2018 to 2025).

We have chosen to present possible trajectories for the forecasts, instead of the usual average forecasts (since when the series are stationary or show trends and/or seasonality, the forecasts do not usually tend towards the process average), through a simulation of the adjusted model. Both for the simulation of future trajectories and for the calculation of the respective confidence intervals of the predictions, errors were considered as random variables, normally distributed, with a mean and standard deviation equal to their estimated values.
All of the analyses were performed using the statistical software R Studio® version 3.5.2 (https://rstudio.com).

Ethics approval and consent to participate
In compliance with Resolution 499/2012 of the National Health Council, the study was approved by the Research Ethics Committee of Nursing College of Ribeirão Preto, University of São Paulo under the Certificate of Ethical Appraisal number 87696318.3.0000.5393 issued on April 30, 2019. Consent to participate was not applicable, because the work was performed using secondary data from cases diagnosed with TB and reported on TBWeb.

Results
Between 2006 and 2017, 2259 TB cases were reported in Ribeirão Preto, the majority of which were pulmonary (77.9%). Fig 1 shows the time series of incidence rates per 100,000 inhabitants.

Table 1 shows the frequency of distribution of TB cases grouped by type, the annual rate and the AMPC.

Fig 1 shows a decrease in the incidence rate of TB-HIV co-infection, which can be proved through the AMPC, showing a decrease of 0.69% per month, as seen in Table 1. It is also possible to verify that general and pulmonary TB decreased by 0.01% per month, and that extrapulmonary TB decreased by 0.33% per month, although these reductions are less noticeable when analyzed in Fig 1.

![Fig 1. Tuberculosis incidence rates in Ribeirão Preto, São Paulo, Brazil (2006–2017).](https://doi.org/10.1371/journal.pone.0252375.g001)
With the breakpoint technique, it is possible to identify the time series structure changes. For general and pulmonary TB, the series structure changed in late 2007, whereas the series for the incidence rates of extrapulmonary TB and TB-HIV co-infection show a break after 2014, which is the cut-off point considered in this study because it marks the beginning of TB diagnosis using the rapid molecular test for TB. Fig 2 shows the breakpoint technique and the various confidence intervals.

With the KPSS unit root test, a value of 0.65 was obtained for general TB (the series is non-stationary), 0.65 for pulmonary TB (non-stationary series), 0.37 for extrapulmonary TB (stationary series) and 1.03 for TB-HIV co-infection (non-stationary series). Thus, it was necessary to use the transformations for the series identified as non-stationary.

For general TB, pulmonary TB and TB-HIV co-infection, the best adjusted models were of ARIMA type (0,1,3), or simply IMA(3). For general TB, only the constant and the coefficient

| Tuberculosis          | Absolute frequency (%) | Annual rate (100,000 inhab.) | Average Monthly Percentage Change (%) |
|-----------------------|------------------------|-----------------------------|---------------------------------------|
| General               | 2259 (100%)            | 31.7                        | -0.01                                 |
| Pulmonary             | 1760 (77.9%)           | 23.2                        | -0.01                                 |
| Extrapulmonary        | 497 (22.0%)            | 6.4                         | -0.33                                 |
| TB-HIV co-infection   | 510 (22.6%)            | 6.7                         | -0.69                                 |

https://doi.org/10.1371/journal.pone.0252375.t001

Fig 2. Changes in the structure of the time series regarding the incidence rates of tuberculosis in Ribeirão Preto, São Paulo, Brazil (2006–2017).
of order three were significant; for pulmonary TB, only the coefficient of order three was significant; and for TB-HIV co-infection, the coefficients of orders two and three were significant. For extrapulmonary TB, the best model found was an ARIMA(5,0,0), or simply the AR(5) model, with all the coefficients being significant, except for the coefficient of order two.

After choosing the best models, we proceeded to analyze the residues. It is possible to observe (Fig 3 and Table 2) that the residues are statistically unrelated and that the remaining

Table 2. Analysis of residues from the temporal modeling of tuberculosis rates, Ribeirão Preto, São Paulo, Brazil (2006–2017).

| Test                      | General TB | Pulmonary TB | Extrapulmonary TB | TB-HIV co-infection |
|---------------------------|------------|--------------|--------------------|---------------------|
| Ljung-Box                 | 0.04 (0.83)| 0.24 (0.61)  | 0.14 (0.70)        | 1.54 (0.21)         |
| Box-Pierce                | 0.044 (0.83)| 0.24 (0.62) | 0.13 (0.70)        | 1.51 (0.21)         |
| Rank test                 | 0.82 (0.40)| 0.82 (0.40)  | -2.16 (0.30)       | 0.97 (0.33)         |
| Turning Point             | -0.33 (0.74)| -0.92 (.035)| 1.06(0.28)         | 0.66 (0.50)         |
| Difference Sign Test      | 0.14 (0.88)| -0.71 (0.47) | -1.00 (0.31)       | -0.71 (0.47)        |
| Bartlett B test           | 0.45 (0.98)| 0.57 (0.90)  | 0.95 (0.31)        | 0.76 (0.59)         |
| Kolmogorov–Smirnov        | 0.04 (0.92)| 0.04 (0.96)  | 0.04 (0.88)        | 0.06 (0.60)         |
| T test of means           | -0.63 (0.52)| -1.32 (0.18)| 0.07 (0.94)        | -1.10 (0.27)        |

https://doi.org/10.1371/journal.pone.0252375.t002
assumptions of the models are validated (independent and identically distributed residues, with a normal distribution of zero mean and constant variance), considering a significance level of 5%.

The quality of the forecasts was analyzed by comparison with the subset of tests (years 2016 and 2017) as seen in Table 3.

Fig 4 shows the final models for the series; it is possible to observe that all of the adjustments are able to capture the variability of all of the series under analysis in a very satisfactory way.

**Discussion**

The study aimed to assess the effectiveness of GeneXpert® MTB/RIF for the detection of pulmonary TB, extrapulmonary TB and TB-HIV co-infection and to predict the rates of disease in the coming years if the routine activities of health teams in this municipality of south-eastern Brazil are maintained. Among the limitations of the study includes the use of secondary data sources, which can lead to incomplete data or typos.
With the analysis of AMPC (Table 1), it is possible to note that, among the groups analyzed in the present study, TB-HIV co-infection showed the greatest decrease (0.69% per month). This can be explained by the greater sensitivity of the rapid molecular test for TB.

Studies show that for a sputum sample in which sputum smear and culture showed positive results, the sensitivity of the rapid molecular test for TB can vary between 98 and 100%. For cases in which the sputum sample has a negative result and a positive culture, the sensitivity of the rapid molecular test for TB decreases to 57 to 78%. For people with negative clinical examination and who had sputum samples with a positive culture result, the specificity of the rapid molecular test for TB can vary between 91% and 100% [2].

For cases in which the culture result is negative, but the person with suspected TB has a positive clinical examination, the specificity of the rapid molecular test for TB is also about 91% but goes to 100% when the sputum sample it has negative sputum smear and culture and is between 94 and 100% when the sputum sample shows only negative culture [2].

Thus, in view of the findings of the study, in addition to the greater sensitivity of the rapid molecular test for TB, the hypothesis is that this decrease in TB-HIV co-infection rate may be related to the greater adherence of people living with HIV to the antiretroviral therapy or positive changes in drug regimens to decrease viral load; this would result in an increase in the immunity of people living with HIV and, therefore, in preventing M. tuberculosis infection [20–22].

With the breakpoint analysis, it was possible to identify that the incidence rates for extrapulmonary TB and TB-HIV co-infection showed a change in the structure of its time series after 2014, which is the cut-off point considered in this study as it marks the beginning of TB diagnosis through the rapid molecular test for TB. This change in the time series may indicate that, among other factors, the diagnosis using the rapid molecular test for TB might have been responsible for causing this change in TB rates in the municipality due to its greater sensitivity and specificity.

Regarding extrapulmonary TB, a study showed that the positivity rates for histology or cytology, GeneXpert MTB/RIF and culture were 12.88%, 20.59% and 15.82%, respectively. The sensitivity and specificity of the rapid molecular test for TB were almost the same in the pulmonary and extrapulmonary samples (78.2% and 90.4%) and (79.3% and 90.3%), respectively [23], however it is worth noting that when the culture was used as the gold standard, the sensitivity and specificity of GeneXpert MTB/RIF were determined for pulmonary and extrapulmonary TB.

According to the literature [5], most of the articles which analyzed the effectiveness of the rapid molecular test for TB used sputum samples; the studies that evaluated extrapulmonary samples showed good test performance, but it is worth noting that the test was more sensitive for sputum samples in most studies.

According to a literature review [5], most of the studies that analyzed the effectiveness of the GeneXpert MTB/RIF assay used sputum samples and although the studies that evaluated extrapulmonary samples have shown satisfactory results [24–28], but it is important that further studies are carried out with this type of material, as this result may vary according to the number of samples tested, the nature of the different extrapulmonary TB samples and also the specific differences that can be found in the different epidemiological contexts, but despite these biases, it is noteworthy that in most studies carried out the GeneXpert MTB/RIF system pointed out that it was the most sensitive test for pulmonary TB, the transmissible form of the disease; however, with the current data found in the literature, there is now support for the use of this method in extrapulmonary samples.

Therefore, in view of the above, health professionals have a good scientific basis for recommending the performance of the rapid molecular test for TB in the GeneXpert MTB/RIF
system for suspected cases of extrapulmonary TB, although other diagnostic tests must also be used to confirm diagnosis accurately.

Another study showed that, in samples of urine and bone or joint fluid and tissue, the rapid molecular test was sensitive (more than 80%), meaning that it has a low chance of resulting in a false positive. In cerebrospinal fluid, pleural fluid and peritoneal fluid, the rapid molecular test was highly specific (98% or more), with a low chance of resulting in a false negative [29]; however, it is worth noting that studies have not shown good efficacy with the GeneXpert® assay in samples of pleural fluid [5,30–32].

Therefore, although there are other techniques for detecting extrapulmonary TB, such as histopathology, the use of the rapid molecular test performed using the GeneXpert® MTB/RIF system is safe and has high sensitivity and specificity when compared to the usual tests.

Across the world, the most commonly used tests for the diagnosis of TB are the sputum smear and sputum culture tests (only for pulmonary TB, in cases of extrapulmonary TB, diagnostic tests are performed with other materials). As it is simpler, faster and less costly, smear microscopy ends up being more commonly used as a routine test by health systems, but it is worth mentioning that it has low sensitivity, especially in cases with low bacillary load [33,34].

The sensitivity of the culture varied between 70% and 90% when the sample of the material was correctly collected, stored and all procedures for carrying out the test were correctly followed by the responsible professional, using a work-intensive method that requires qualified professionals for the examination to be carried out accurately and reliably. It takes about 14 to 60 days to get a result with this technique and due to the long period required to reach a diagnosis, culture is rarely used to make decisions regarding the treatment of a person with TB [33,34]. It is worth mentioning that the most used culture media are solids, but liquid culture performed in an automated system has advantages.

According to the Brazilian report of the National Commission for the Incorporation of Technologies in SUS (CONITEC), for the automated liquid culture, the average proportion of mycobacterial detection obtained was 82% (95% CI, 71% to 90%), and 65% (95% CI 51% to 77%) for culture in solid medium. The average time for detection by the automated liquid culture system was 14 days and for solid culture it was 28 days. Regarding the sensitivity test performed in the automated liquid culture system, in general, a high level of agreement with the method of proportions in solid culture (>90%) was identified. Thus, the use of automated systems could increase the coverage of testing across the country, constituting an important strategy for the diagnosis and control of TB [35].

Still regarding liquid culture, a review study found that the highest sensitivities and negative predictive values were shown by the MGIT-960 System when used alone or in combination with the Lowenstein-Jensen method, with the combined media showing better sensitivity as well as obtaining satisfactory results in the detection of non-tuberculous mycobacteria. The greater specificity and positive predictive values were shown by the Lowenstein-Jensen method alone, which did not produce false positives [36].

In another study carried out in a laboratory in South Africa [37], results point to the high cost of MGIT-960 and its cost-benefit must be carefully evaluated taking into account its sensitivity and high probability of cross contamination, as was also reported in another study [38] that compared solid and liquid media for culture.

It is possible to conclude that the MGIT-960 has a better performance regarding sensitivity, while the Lowenstein-Jensen method has greater specificity; the MGIT-960 system can provide a better isolation rate of mycobacteria from sputum samples from people suspected of having pulmonary TB when compared to culture in a solid medium (Lowenstein-Jensen) [39–41]. Therefore, in accordance with current international guidelines, a combination of solid and
liquid media is recommended, so that the number of positive findings can be significantly increased.

Returning to the rapid molecular test for TB performed using the GeneXpert® system, its main advantages are that the result can be released within two hours and will already indicate whether the patient is resistant or sensitive to rifampicin [42]. Thus, it is possible that the incorporation of the GeneXpert® system into the Brazilian health system may be related to changes in disease rates since more people may be diagnosed due to the high sensitivity, specificity and rapid time of diagnosis of the GeneXpert® system when compared to the usual tests and, therefore, it could also be responsible for a consequent change in the structure of the analyzed time series, since any change in the indexes (be it rate or number of cases) alters its history series over time.

Using the Box–Jenkins [18] methodology, a well-estimated model that provides adequate forecasts, can be a very useful tool to assist with decision-making by both public managers and society [43]. From the adjustment of the models, it was possible to verify and make forecasts for the TB rates in Ribeirão Preto; although the estimates indicate a slight decrease, TB will continue to be a serious public health problem.

Considered a priority by the Brazilian government since 2003, TB has been the subject of several national agreements and has been made a priority of the National Tuberculosis Control Program (NTCP). There has been an increase in the detection of cases through the strengthening of the primary health care services system [44,45].

According to the TB diagnosis algorithm recommended by the Ministry of Health, all new suspected cases of pulmonary TB must be tested using a rapid molecular test. If both MTB and resistance to rifampicin are detected, another confirmatory rapid molecular test should be performed, combined with a culture test and drug susceptibility test, and the patient should be referred for specialist attention. If rifampicin-sensitive MTB is detected, treatment with the basic TB regimen is started, but in addition, culture and sensitivity testing must be performed to check resistance to other drugs used in the treatment [4].

The rapid molecular test for TB performed by the GeneXpert® MTB/RIF system has several positive points when compared to classic methods for TB diagnosis; however, further studies will improve the understanding of this test and contribute to the diagnosis of TB.

In the scenario under investigation, the tests are being carried out with the new systems called GeneXpert® Ultra and GeneXpert® Omni, which are evolutions of the GeneXpert® system used in Brazil and which have been shown to be more sensitive and specific; these may have relevant implications for the health services system and an impact on disease rates, as identified in the present study. However, it is important to understand the changes or impacts that occurred in the epidemiological indicators and health services with the diagnosis of TB being made through the rapid molecular test and its progression [46–48].

The study provides advances in knowledge as it presents the impact of rapid molecular testing for TB on routine health services, and it is important to note that studies of this design are able to support decisions about the maintenance and/or sustainability of technologies in a real, uncontrolled context.

Conclusions

The rapid molecular test for TB performed by the GeneXpert® MTB/RIF system is the method currently recommended by the Ministry of Health for the diagnosis of TB. Its main advantage is that it gives a faster and more accurate diagnosis when compared to other classic diagnostic methods, such as smear microscopy and culture tests.

It is necessary for managers responsible for the Tuberculosis Control Programs to encourage professionals who deal with people suspected or diagnosed with TB to comply with the
algorithm recommended by the WHO in order to optimize the diagnosis so that the technologies are used correctly, meaning that a more accurate diagnosis is carried out so that the treatment can start as quickly as possible and correctly, taking into account whether the identified strain is resistant to the drugs used or not. Only by uniting professionals from all areas with health policies aimed at early case identification and rapid treatment initiation is it possible to break the chain of TB transmission so that its rates decrease and the goals proposed by the WHO are achieved.

Supporting information
S1 Dataset.
(CSV)

Acknowledgments
Municipal Health Secretariat of Ribeirão Preto.
Municipal Tuberculosis Control Program of Ribeirão Preto.

Author Contributions
Conceptualization: Thaísa Zamboni Berra, Dulce Gomes, Ricardo Alexandre Arcêncio.
Data curation: Thaísa Zamboni Berra.
Formal analysis: Thaísa Zamboni Berra, Dulce Gomes.
Investigation: Thaísa Zamboni Berra, Dulce Gomes, Ricardo Alexandre Arcêncio.
Methodology: Thaísa Zamboni Berra, Dulce Gomes.
Supervision: Ricardo Alexandre Arcêncio.
Writing – original draft: Thaísa Zamboni Berra, Dulce Gomes, Ricardo Alexandre Arcêncio.
Writing – review & editing: Thaísa Zamboni Berra, Dulce Gomes, Antônio Carlos Vieira Ramos, Yan Mathias Alves, Alexandre Tadashi Inomata Bruce, Luiz Henrique Arroyo, Felipe Lima dos Santos, Ludmilla Leideanne Limirio Souza, Juliane de Almeida Crispim, Ricardo Alexandre Arcêncio.

References
1. World Health Organization (WHO). Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. Accessed: January 11, 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.
2. Brasil. Agência Nacional de Vigilância Sanitária. Xpert® MTB/RIF no diagnóstico da tuberculose pulmonar. Boletim Brasileiro de Avaliação de Tecnologias em Saúde. 2011. Accessed: May 28, 2020. Available from: http://bvsms.saude.gov.br/bvs/periodicos/brats_16.pdf.
3. Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010; 10(7):937–46. Accessed: May 28, 2020. Available from: https://www.tandfonline.com/doi/full/10.1586/erm.10.67. PMID: 20964612
4. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Programa Nacional de Controle da Tuberculose. Manual de Recomendações para o Controle da Tuberculose no Brasil. Brasília, 2019. Accessed: May 28, 2020. Available from: https://www.saude.mg.gov.br/images/documentos/manual_recomendacoes_tb_2ed_atualizada_8maio19.pdf.
5. Lima TM, Belotti NCU, Nardi SMT, Pedro HSP. GeneXpert MTB/RIF assay for diagnosis of tuberculosis. Rev Pan-Amaz Saude 2017; 8(2):67–78. Accessed: May 28, 2020. Available from: http://scielo.iiec.gov.br/pdf/rpas/v8n2/2176-6223-rpas-8-02-00065.pdf.
6. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dedukuri N. Xpert® MTB/RIF Assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014; 2014(1):CD009593. Accessed: May 28, 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/24448973/. https://doi.org/10.1002/14651858.CD009593.pub3 PMID: 24448973

7. Vassal A, Van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Medicine 2011; 8(11):e1001120. Accessed: May 28, 2020. Available from: https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1001120&type=printable. https://doi.org/10.1371/journal.pmed.1001120 PMID: 22087079

8. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation PLoS Med 2012; 9(11). Accessed: May 28, 2020. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001347 PMID: 23185139

9. Choi HM, Miele K, Dowdy D, Shah M. Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States. Int J Tuberc Lung Dis 2013; 17(10):1328–35. Accessed: May 28, 2020. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3891798/pdf/nihms-540965.pdf. https://doi.org/10.5588/ijtld.13.0095 PMID: 24025386

10. Cepheid. Sunnyvale (CA): Cepheid. The New GeneXpert® System. New Systems. Same game-changing performance. Accessed: May 28, 2020. Available from: https://pdf.medicalexpo.com/pdf/cephied/new-genexpert/67984-218969.html

11. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. John Wiley & Sons, 1982. https://doi.org/10.1210/jcem-55-4-787 PMID: 7107822

12. Ribeirão Preto. Prefeitura Municipal. Secretaria Municipal de Saúde. Accessed: May 28, 2020. Available from: https://www.ribeiraoporto.sp.gov.br/ssauede/programas124.pdf.

13. Galesi VMN. Data on tuberculosis in the state of São Paulo, Brazil. Rev Saúde Pública 2015; 24(3):565–576. Accessed: May 28, 2020. Available from: https://www.scielo.br/pdf/rsp/v42n3/2237-9622-resp-42-03-00565.pdf.

14. Zeileis A, Leisch F, Hornik K, Kleiber C, Hansen B, Merkle EC. Package ‘strucchange’. CRAN repository 2019. Accessed: May 28, 2020. Available from: https://cran.r-project.org/web/packages/strucchange/strucchange.pdf.

15. Zeileis A, Kleiber C, Kramer W, Hornik K. Testing and dating of structural changes in practice. Computational Statistics & Data Analysis 2003; 44(1–2):109–123. Accessed: May 28, 2020. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0167947303003066.

16. Becketti S. Introduction to Time Series using Stata. College Station: Stata Press, 2013.

17. Box GEP, Jenkins GM. Time Series Analysis, Forecasting and Control. San Francisco: Holden-Day, Inc., 1970.

18. Brockwell PJ, Davis RA. Introduction to Time Series and Forecasting. 2nd ed. New York: Springer-Verlag, 2002.

19. Souza HC, Mota MR, Alves AR, et al. Analysis of compliance to antiretroviral treatment among patients with HIV/AIDS. Rev Bras Enferm 2019; 72(5):1295–303. Accessed: May 28, 2020. Available from: https://www.scielo.br/pdf/rbene/v72n5/0034-7167-reben-72-05-1295.pdf. https://doi.org/10.1590/s0034-8910201900500017 PMID: 31531654

20. Costa JO, Ceccato MGB, Silveira MR, Bonolo PF, Reis EA, Accurso FA. Effectiveness of antiretroviral therapy in the single-tablet regimen era. Rev Saude Publica 2018; 52:87. Accessed: May 28, 2020. Available from: https://www.scielo.br/pdf/rsp/v41s1/carta.pdf. https://doi.org/10.1590/s0102-14652017005000015 PMID: 31531654

21. Seidl EMF, Melchiades A, Farias V, Brito A. Persons living with HIV/AIDS: factors associated with adherence to antiretroviral treatment. Cad Saude Publica 2007; 23(10):2305–2316. Accessed: May 28, 2020. Available from: https://www.scielo.br/pdf/csp/v23n10/06.pdf. https://doi.org/10.1590/s0102-311x2007010100006 PMID: 17891292

22. Mechal Y, Neaissa E, El Miramar N, Benlahlou Y, Bssaibis F, Zegmout A et al. Evaluation of GeneXpert MTB/RIF® system performances in the diagnosis of extrapulmonary tuberculosis. BMC Infectious Diseases 2012; 12(1):1069. Accessed: January 11, 2021. https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-12-1069.

23. Armand S, Vanhuls P, Delcroix G, Courcol R, Lemaitre N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol. 2011; 49(5):1772–6. Accessed: March 30, 2021.
25. Vadwai V, Boehme C, Nabeta P, Shetty A, Aliand D, Rodrigues C. Xpert MTB/RIF: a new pillar in diagnosis of extrapulmonary tuberculosis? J Clin Microbiol. 2011; 49(7):2540–5. Accessed: March 30, 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3147857/. https://doi.org/10.1128/JCM.02319-10 PMID: 21593262

26. Patel VB, Theron G, Lenders L, Matinyena B, Connolly C, Singh R, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculosis meningitis in a high burden setting: a prospective study. PLoS Med. 201310(10): e1001536. Accessed: March 30, 2021. Available from: https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001536.

27. Sekadde MP, Wobudeya E, Joloba ML, Ssengobwa W, Kisembo H, Bakeera-Kitaka S, et al. Evaluation of the Xpert MTB/RIF test for the diagnosis of childhood pulmonary tuberculosis in Uganda: a cross-sectional diagnostic study. BMC Infect Dis. 2013; 13(133):1–8. Accessed: March 30, 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3602671/.

28. Vallejo V P, Rodríguez D JC, Searle M A, Farga C V. Ensayo Xpert MTB/RIF en el diagnostico de tuberculosis: performance and cost in a resource-constrained setting. Rev Chil Enferm Respir. 2015; 31(2):127–31. Accessed: March 30, 2021. Available from: https://scielo.conicyt.cl/pdf/rcher/v31n2/art10.pdf.

29. Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger CM, Schumacher SG et al. Xpert® MTB/RIF test for diagnosing extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews 2018; 8(CD012768). Accessed: January 11, 2021. Available from: https://www.cochranelibrary.com/cdrl/doi/10.1002/14651858.CD012768.pub2/pdf/abstract. PMID: 30148542

30. Sehgal IS, Dhoria S, Aggarwal AN, Behera D, Agarwal R. Diagnostic performance of Xpert MTB/RIF in tuberculous pleural effusion: Systematic review and meta-analysis. J Clin Microbiol 2016; 54(4):1133–6. Accessed: February 22, 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/26818675/. https://doi.org/10.1128/JCM.03205-15 PMID: 26818675

31. Rufai SB, Singh A, Kumar P, Singh J, Singh S. Performance of Xpert MTB/RIF assay in diagnosis of pleural tuberculosis by use of pleural fluid samples. J Clin Microbiol 2015; 53(11):3636–8. Accessed: February 22, 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/26311855/. https://doi.org/10.1128/JCM.02182-15 PMID: 26311855

32. Denkinger CM, Schumacher SG, Boehme CC, Dendukuri N, Pai M, Steingart KR. Xpert® MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta-analysis. Eur Respir J 2014; 44(2):435–46. Accessed: February 22, 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/24696113/. https://doi.org/10.1183/09031936.0007814 PMID: 24696113

33. Malacarne J, Heirich AS, Cunha EAT, Kolte IV, Souza-Santos R, Basta PC. Desempenho de testes para o diagnóstico de tuberculose pulmonar em populações indígenas no Brasil: a contribuição do Teste Rápido Molecular. J Bras Pneumol. 2019; 45(2):1024–1031. Accessed: February 22, 2021. Available from: https://link.springer.com/content/pdf/10.1007/s10096-014-2105-z.pdf . https://doi.org/10.1007/s10096-014-2105-z PMID: 24760249

34. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância Epidemiológica. Manual Nacional de Vigilância Laboratorial da Tuberculose e outras Micobactérias; 2008. Accessed: May 28, 2020, Available from: http://bvbsms.saude.gov.br/bvs/publicacoes/manual_vigilancia_laboratorial_tuberculose.pdf.

35. Brasil. Ministério da Saúde. Comissão Nacional de Incorporação de Tecnologias no SUS (CONITEC). Relatório de recomendação: Cultura líquida automatizada para detecção de micobactérias e teste de sensibilidade aos antimicrobianos utilizados no tratamento da tuberculose. Brasília-DF, 2020. Accessed: February 22, 2021. Available from: http://conitec.gov.br/images/Consultas/Relatorios/2020/Relatorio_CP_CulturaLiquida_Tuberculose_18_2020.pdf.

36. Rageade F, Picot N, Blanc-Michaud A, Chatellier S, Miranda C, Fortin E et al. Performance of solid and liquid culture media for the detection of Mycobacterium tuberculosis in clinical materials: meta-analysis of recent studies. Eur J Clin Microbiol Infect Dis. 2014; 33:867–870. Accessed: March 30, 2021. Available from: https://link.springer.com/content/pdf/10.1007/s10096-014-2105-z.pdf . https://doi.org/10.1007/s10096-014-2105-z PMID: 24760249

37. Chihota VN, Grant AD, Fielding K, Ndibongo B, Van Zyl A, Muirhead D et.al. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting. Int J Tuberc Lung Dis. 2010; 14(8):1024–1031. Accessed: March 30, 2021. Available from: https://ghdonline.org/uploads/Chihota_IJTLD_2010_Liquid_culture_vs Solid_media_South_Africa.pdf. PMID: 20626948

38. Phillips PPJ, Mendel CM, Nunu AJ, McHugh TD, Crook AM, Hunt R et al. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens. BMC Medicine. 2017; 15:207. Accessed: March 30, 2021. Available from: https://bmcmedicine.biomedcentral.com/track/pdf/10.1186/s12916-017-0955-9.pdf. https://doi.org/10.1186/s12916-017-0955-9 PMID: 29169355
39. Zhao P, Yu Q, Chen L, Zhang M. Evaluation of a liquid culture system in the detection of mycobacteria at an antituberculosis institution in China: A retrospective study. J Int Med Res. 2016; 44(5):1055–1060. Accessed: March 30, 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365555/. PMID: 27688689

40. Mathewos B, Kebede N, Kassa T, Miheret A, Getahun M. Characterization of mycobacterium isolates from pulmonary tuberculosis suspected cases visiting Tuberculosis Reference Laboratory at Ethiopian Health and Nutrition Research Institute, Addis Ababa Ethiopia: a cross sectional study. Asian Pac J Trop Med. 2015; 8(1):35–40. Accessed: March 30, 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562020/. https://doi.org/10.1016/S1995-7645(14)60184-X PMID: 25901922

41. Feyzioglu B, Dogan M, Sanli OO, Ozdemir M, Baykan M. Comparison of the performance of TK system with LJ and MGIT methods in the diagnosis of tuberculosis. Int J Clin Exp Med. 2014; 7(4):1084–1088. Accessed: March 30, 2021. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057865/. PMID: 24955186

42. Kritski A, Andrade KB, Galliez RM, et al. Tuberculosis: renewed challenge in Brazil. Rev Soc Bras Med Trop 2018; 51(1):2–6. Accessed: May 28, 2020. Available from: https://www.scielo.br/pdf/rbsbt/51n11678-9849-rbsbt-51-01-2.pdf. https://doi.org/10.1590/0037-8682-0349-2017 PMID: 29513837

43. Scheffer D, Souza AM, Zanini RR. Utilização de Modelos ARIMA para previsão da arrecadação de ICMS do Estado do Rio Grande do Sul. Blucher Proceedings 2014; 1(1). Accessed: May 29, 2020, Available from: http://pdf.blucher.com.br/a3-sa-east-1.amazonaws.com/marineengineeringproceedings/spolm2014/127111.pdf.

44. World Health Organization (WHO). Using the Xpert MTB/RIF assay to detect pulmonary and extrapulmonary tuberculosis and rifampicin resistance in adults and children. Geneva: WHO, 2013. Accessed: May 28, 2020. Available from: http://www.who.int/iris/bitstream/10665/112659/1/WHOHTM_TB_2013.14_eng.pdf?ua=1.

45. Clementino FS, Marcolino EC, Gomes LB, Guerreiro JV, Miranda FAN. Tuberculosis control actions: analysis based on the access and primary health care quality improvement program. Texto e contexto 2016; 25(4). Accessed: May 29, 2020, Available from: https://www.scielo.br/pdf/tce/v25n4/0104-0707-tce-25-04-4660015.pdf.

46. Garcia-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palermo D, Geggia M et al. Point of care diagnostics for tuberculosis. Pulmonol 2018; 24(2):73–85. Accessed: February 23, 2021. Available from: https://www.journalpulmonology.org/en-pdf-S2173511517301835. https://doi.org/10.1016/j.rppnen.2017.12.002 PMID: 29426581

47. Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jaton K. Added value of Xpert MTB/RIF ultra for the diagnosis of tuberculous in a low-prevalence setting. J Clin Microbiol 2019; 57(2):e01717–18. Accessed: February 23, 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/30541937/ https://doi.org/10.1128/JCM.01717-18 PMID: 30541937

48. Opota O, Mazza-Stalder J, Greub G, Jaton K. The rapid molecular test Xpert MTB/RIF ultra: towards improved tuberculosis diagnosis and rifampicin resistance detection. Clin Microbiol Infect 2019; 25 (11):1370–1376. Accessed: February 23, 2021. Available from: https://pubmed.ncbi.nlm.nih.gov/30928564/. https://doi.org/10.1016/j.cmi.2019.03.021 PMID: 30928564